Overall Survival and Related Factors of Advanced-stage Epithelial Ovarian Cancer Patients Underwent Debulking Surgery in Jakarta, Indonesia: A Single-center Experience
DOI:
https://doi.org/10.3889/oamjms.2022.8296Keywords:
Advanced-stage epithelial ovarian cancer, Debulking surgery, Survival, Cytoreductive surgery, OutcomeAbstract
AIM: The worrisome prognosis of advanced-stage epithelial ovarian cancer (EOC) needs a new perspective from developing countries. Thus, we attempted to study the 5-year overall survival (OS) of advanced-stage EOC patients who underwent debulking surgery in an Indonesian tertiary hospital.
METHODS: A retrospective study recruited forty-eight subjects between 2013 and 2015. We conducted multiple logistic regression analyses to predict risk factors leading to unwanted disease outcomes. The OS was evaluated through the Kaplan–Meier curve and Log-rank test. Cox proportional hazards regression examined prognostic factors of patients.
RESULTS: Prominent characteristics of our patients were middle age (mean: 51.9 ± 8.9 years), obese, with normal menarche onset, multiparous, not using contraception, premenopausal, with serous EOC, and FIGO stage IIIC. The subjects mainly underwent primary debulking surgery (66.8%), with 47.9% of all individuals acquiring optimal results, 77.1% of patients treated had the residual disease (RD), and 52.1% got adjuvant chemotherapy. The risk factor for serous EOC was menopause (odds ratio [OR] = 4.82). The predictors of suboptimal surgery were serous EOC (OR = 8.25) and FIGO stage IV (OR = 11.13). The different OS and median survival were observed exclusively in RD, making it an independent prognostic factor (hazard ratio = 3.50). 5-year A five year OS and median survival for patients with advanced-stage EOC who underwent debulking surgery was 37.5% and 32 months, respectively. Optimal versus suboptimal debulking surgery yielded OS 43.5% versus 32% and median survival of 39 versus 29 months. Both optimal and suboptimal debulking surgery followed with chemotherapy demonstrated an OS 40% lower than those not administered (46.2% and 20%, respectively). The highest 5-year OS was in serous EOC (50%). Meanwhile, the most extended median survival was with mucinous EOC (45 months).
CONCLUSION: Chemotherapy following optimal and suboptimal debulking surgery has the best OS among approaches researched in this study. RD is a significant prognostic factor among advanced-stage EOC. Suboptimal surgery outcomes can be predicted by stage and histological subtype.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660 PMid:33538338 DOI: https://doi.org/10.3322/caac.21660
Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Int J Womens Health. 2019;11:287-99. https://doi.org/10.2147/IJWH.S197604 PMid:31118829 DOI: https://doi.org/10.2147/IJWH.S197604
Farghaly SA. Advances in Diagnosis and Management of Ovarian Cancer. 1st ed. New York, Boston, MA: Springer; 2014. p. 1-270. DOI: https://doi.org/10.1007/978-1-4614-8271-0
Kang JH, Lai YL, Cheng WF, Kim HS, Kuo KT, Chen YL, et al. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: Experiences at two large academic institutions in Korea and Taiwan. Sci Rep. 2020;10(1):20012. https://doi.org/10.1038/s41598-020-77075-1 PMid:33203969 DOI: https://doi.org/10.1038/s41598-020-77075-1
Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140(11):2451-60. https://doi.org/10.1002/ijc.30676 PMid:28257597 DOI: https://doi.org/10.1002/ijc.30676
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-96. https://doi.org/10.3322/caac.21456 PMid:29809280 DOI: https://doi.org/10.3322/caac.21456
World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2020: Indonesia. The Global Cancer Observatory. Geneva: World Health Organization; 2021. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf [Last accessed on 2021 Nov 20].
Wahidin M, Noviani R, Hermawan S, Andriani V, Ardian A, Djarir H. Population-based cancer registration in Indonesia. Asian Pac J Cancer Prev. 2012;13(4):1709-10. https://doi.org/10.7314/apjcp.2012.13.4.1709 PMid:22799393 DOI: https://doi.org/10.7314/APJCP.2012.13.4.1709
Sfakianos GP, Havrilesky LJ. A review of cost-effectiveness studies in ovarian cancer. Cancer Control. 2011;18(1):59-64. https://doi.org/10.1177/107327481101800109 PMid:21273981 DOI: https://doi.org/10.1177/107327481101800109
Gao Y, Li Y, Zhang C, Han J, Liang H, Zhang K, et al. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: A retrospective study. J Ovarian Res. 2019;12(1):85. https://doi.org/10.1186/s13048-019-0562-9 PMid:31519183 DOI: https://doi.org/10.1186/s13048-019-0562-9
Altman AD, Nelson G, Chu P, Nation J, Ghatage P. Optimal debulking targets in women with advanced stage ovarian cancer: A retrospective study of immediate versus interval debulking surgery. J Obstet Gynaecol Canada. 2012;34(6):558-66. https://doi.org/10.1016/S1701-2163(16)35272-0 PMid:22673172 DOI: https://doi.org/10.1016/S1701-2163(16)35272-0
Dahlan MS. Analisis Multivariat Regresi Logistik. 2nd ed. Jakarta: Epidemiologi Indonesia; 2019. p. 1-175.
Dahlan MS. Analisis Survival: Dasar-Dasar Teori and Aplikasi Dengan Program SPSS. 1st ed. Jakarta: Epidemiologi Indonesia; 2012. p. 1-90.
Laerd Statistics. Kaplan-Meier using SPSS Statistics. Lund Research Ltd.; 2018. Available from: https://statistics.laerd.com/spss-tutorials/kaplan-meier-using-spss-statistics.php [Last accessed on 2020 Nov 23].
Terplan M, Schluterman N, McNamara EJ, Tracy JK, Temkin SM. Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. Gynecol Oncol. 2012;125(1):19-24. https://doi.org/10.1016/j.ygyno.2011.11.025 PMid:22108636 DOI: https://doi.org/10.1016/j.ygyno.2011.11.025
Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. Gynecol Oncol. 2013;129(1):258-64. https://doi.org/10.1016/j.ygyno.2012.12.016 PMid:23266352 DOI: https://doi.org/10.1016/j.ygyno.2012.12.016
Suknikhom W, Muangtan S, Sananpanichkul P. Histopathological patterns of epithelial ovarian cancer at Prapokklao hospital: A five years retrospective study. 2018;35(3):257-267.
Lundberg FE, Iliadou AN, Rodriguez-Wallberg K, Gemzell- Danielsson K, Johansson AL. The risk of breast and gynecological cancer in women with a diagnosis of infertility: A nationwide population-based study. Eur J Epidemiol. 2019;34(5):499-507. https://doi.org/10.1007/s10654-018-0474-9 PMid:30623293 DOI: https://doi.org/10.1007/s10654-018-0474-9
Shen F, Chen S, Gao Y, Dai X, Chen Q. The prevalence of malignant and borderline ovarian cancer in pre-and postmenopausal Chinese women. Oncotarget. 2017;8(46):80589-94. https://doi.org/10.18632/oncotarget.20384 PMid:29113327 DOI: https://doi.org/10.18632/oncotarget.20384
Kamajaya IG, Brahmantara BN, Wirawan AN. Profile of ovarian cancer patients in Mangusada Badung regional public hospital. Indones J Cancer. 2021;15(3):117. DOI: https://doi.org/10.33371/ijoc.v15i3.774
Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2002;11(9):822-8. PMid:12223425
Noela F, Nuryanto KH. Epidemiology data of ovarian cancer in Dr. Cipto Mangunkusumo Hospital, Jakarta. Indones J Obstet Gynecol. 2016;4(2):101. DOI: https://doi.org/10.32771/inajog.v4i2.84
Bandera CA. Advances in the understanding of risk factors for ovarian cancer. J Reprod Med. 2005;50(6):399-406. PMid:16050564
Batubara JRL, Soesanti F, van de Waal HD. Age at menarche in Indonesian girls: A national survey. Acta Med Indones. 2010;42(2):78-81. PMid:20513931
Nnoaham KE, Webster P, Kumbang J, Kennedy SH, Zondervan KT. Is early age at menarche a risk factor for endometriosis? A systematic review and meta-analysis of casecontrol studies. Fertil Steril. 2012;98(3):702-12. https://doi.org/10.1016/j.fertnstert.2012.05.035 PMid:22728052 DOI: https://doi.org/10.1016/j.fertnstert.2012.05.035
Lacroix AE, Gondal H, Langaker MD. Physiology, Menarche. Treasure Island, FL: StatPearls; 2021.
Fujita M, Tase T, Kakugawa Y, Hoshi S, Nishino Y, Nagase S, et al. Smoking, earlier menarche and low parity as independent risk factors for gynecologic cancers in Japanese: A case-control study. Tohoku J Exp Med. 2008;216(4):297-307. https://doi.org/10.1620/tjem.216.297 PMid:19060444 DOI: https://doi.org/10.1620/tjem.216.297
Jordan SJ, Webb PM, Green AC. Height, age at menarche, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(8):2045-8. https://doi.org/10.1158/1055-9965.EPI-05-0085 PMid:16103459 DOI: https://doi.org/10.1158/1055-9965.EPI-05-0085
Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer. 2001;84(5):714-21. https://doi.org/10.1054/bjoc.2000.1596 PMid:11237375 DOI: https://doi.org/10.1054/bjoc.2000.1596
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: A review. Cancer Biol Med. 2017;14(1):9-32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084 PMid:28443200 DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0084
Gaitskell K, Green J, Pirie K, Barnes I, Hermon C, Reeves GK, et al. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study. Int J Cancer. 2018;142(2):281-9. https://doi.org/10.1002/ijc.31063 PMid:28929490 DOI: https://doi.org/10.1002/ijc.31063
Kobayashi H. Potential scenarios leading to ovarian cancer arising from endometriosis. Redox Rep. 2016;21(3):119-26. https://doi.org/10.1179/1351000215Y.0000000038 PMid:26317761 DOI: https://doi.org/10.1179/1351000215Y.0000000038
Su D, Pasalich M, Lee AH, Binns CW. Ovarian cancer risk is reduced by prolonged lactation: A case-control study in Southern China. Am J Clin Nutr. 2013;97(2):354-9. https://doi.org/10.3945/ajcn.112.044719 PMid:23283498 DOI: https://doi.org/10.3945/ajcn.112.044719
Braem MG, Onland-Moret NC, van den Brandt PA, Goldbohm RA, Peeters PH, Kruitwagen RF, et al. Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol. 2010;172(10):1181-9. https://doi.org/10.1093/aje/kwq264 PMid:20861144 DOI: https://doi.org/10.1093/aje/kwq264
Budiana IN, Angelina M, Pemayun TG. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. J Turk Ger Gynecol Assoc. 2019;20(1):47-54. https://doi.org/10.4274/jtgga.galenos.2018.2018.0119 PMid:30362670 DOI: https://doi.org/10.4274/jtgga.galenos.2018.2018.0119
Fathalla MF. Incessant ovulation and ovarian cancer a hypothesis re-visited. Facts views Vis Obgyn. 2013;5(4):292-7. PMid:24753957
Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol. 2007;166(8):894-901. PMid:17656616 DOI: https://doi.org/10.1093/aje/kwm157
Berchuck A, Schildkraut J. Oral contraceptive pills. Prevention of ovarian cancer and other benefits. N C Med J. 1997;58(6):404-7; discussion 408. PMid:9392951
Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch WR, Vitonis AF, Berkowitz RS, et al. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1125-31. https://doi.org/10.1158/1055-9965.EPI-05-0035 PMid:15894662 DOI: https://doi.org/10.1158/1055-9965.EPI-05-0035
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet (London, England). 2014;384(9951):1376-88. https://doi.org/10.1016/S0140-6736(13)62146-7 PMid:24767708 DOI: https://doi.org/10.1016/S0140-6736(13)62146-7
Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, et al. Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. Lancet (London, England). 2015;385(9980):1835-42. https://doi.org/10.1016/S0140-6736(14)61687-1 PMid:25684585 DOI: https://doi.org/10.1016/S0140-6736(14)61687-1
Deng F, Xu X, Lv M, Ren B, Wang Y, Guo W, et al. Age is associated with prognosis in serous ovarian carcinoma. J Ovarian Res. 2017;10(1):36. https://doi.org/10.1186/s13048-017-0331-6 PMid:28606125 DOI: https://doi.org/10.1186/s13048-017-0331-6
Akgöl S, Aktürk E, Özaydın İY, Ölmez F, Karakaş S, Oğlak SC, et al. Serous epithelial ovarian cancer: Retrospective analysis of 260 cases. Aegean J Obstet Gynecol. 2021;3(1):19-21. DOI: https://doi.org/10.46328/aejog.v3i1.83
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-53. https://doi.org/10.1056/NEJMoa0908806 PMid:20818904 DOI: https://doi.org/10.1056/NEJMoa0908806
Mizuno M, Kajiyama H, Shibata K, Mizuno K, Kawai M, Nagasaka T, et al. Prognostic value of histological type in stage IV ovarian carcinoma: A retrospective analysis of 223 patients. Br J Cancer. 2015;112(8):1376-83. https://doi.org/10.1038/bjc.2015.97 PMid:25867257 DOI: https://doi.org/10.1038/bjc.2015.97
Lisio M-A, Fu L, Goyeneche A, Gao Z-H, Telleria C. Highgrade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20(4):952. https://doi.org/10.3390/ijms20040952 PMid:30813239 DOI: https://doi.org/10.3390/ijms20040952
Weng CS, Wu CC, Chen TC, Chen JR, Huang CY, Chang CL. Retrospective analysis of comparative outcomes in recurrent platinum-sensitive ovarian cancer treated with pegylated liposomal doxorubicin (Lipo-dox) and carboplatin versus paclitaxel and carboplatin. Cancer Manag Res. 2019;11:9899-905. https://doi.org/10.2147/CMAR.S217329 PMid:31819627 DOI: https://doi.org/10.2147/CMAR.S217329
Chang LC, Huang CF, Lai MS, Shen LJ, Wu FL, Cheng WF. Prognostic factors in epithelial ovarian cancer: A populationbased study. PLoS One. 2018;13(3):e0194993. https://doi.org/10.1371/journal.pone.0194993 PMid:29579127 DOI: https://doi.org/10.1371/journal.pone.0194993
Zhou J, Wu SG, Wang J, Sun JY, He ZY, Jin X, et al. The effect of histological subtypes on outcomes of stage IV epithelial ovarian cancer. Front Oncol. 2018;8:577. https://doi.org/10.3389/fonc.2018.00577 PMid:30564556 DOI: https://doi.org/10.3389/fonc.2018.00577
Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010;171(1):45-53. PMid:19910378 DOI: https://doi.org/10.1093/aje/kwp314
Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL. Age at menarche and risk of ovarian cancer: A meta-analysis of epidemiological studies. Int J Cancer. 2013;132(12):2894-900. https://doi.org/10.1002/ijc.27952 PMid:23175139 DOI: https://doi.org/10.1002/ijc.27952
Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, et al. Ovarian cancer risk factors by histologic subtype: An analysis from the ovarian cancer cohort consortium. J Clin Oncol. 2016;34(24):2888-98. PMid:27325851
Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP diet and health study. Int J Cancer. 2012;131(4):938-48. https://doi.org/10.1002/ijc.26469 PMid:21960414 DOI: https://doi.org/10.1002/ijc.26469
Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250-63. https://doi.org/10.1093/jnci/djq526 PMid:21191117 DOI: https://doi.org/10.1093/jnci/djq526
Arab M, Jamdar F, Hosseini MS, Ghodssi-Ghasemabadi R, Farzaneh F, Ashrafganjoei T. Model for prediction of optimal debulking of epithelial ovarian cancer. Asian Pac J Cancer Prev. 2018;19(5):1319-24. https://doi.org/10.22034/APJCP.2018.19.5.1319 PMid:29802693
Feng LY, Liao S Bin, Li L. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: A preliminary model study. J Ovarian Res. 2020;13(1):17. https://doi.org/10.1186/s13048-020-0614-1 PMid:32050995 DOI: https://doi.org/10.1186/s13048-020-0614-1
Llueca A, Climent MT, Escrig J, Carrasco P, Serra A, Gomez-Quiles L, et al. Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer. Sci Rep. 2021;11(1):1-8. DOI: https://doi.org/10.1038/s41598-021-86928-2
Gu Y, Qin M, Jin Y, Zuo J, Li N, Bian C, et al. A prediction model for optimal primary debulking surgery based on preoperative computed tomography scans and clinical factors in patients with advanced ovarian cancer: A multicenter retrospective cohort study. Front Oncol. 2021;10:611617. DOI: https://doi.org/10.3389/fonc.2020.611617
Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Metaanalysis of 21 studies. Ann Surg Oncol. 2009;16(8):2315-20. https://doi.org/10.1245/s10434-009-0558-6 PMid:19517192 DOI: https://doi.org/10.1245/s10434-009-0558-6
Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RF. No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer. 2018;88:31-7. https://doi.org/10.1016/j.ejca.2017.10.030 PMid:29179135 DOI: https://doi.org/10.1016/j.ejca.2017.10.030
Neesham D, Richards A, McGauran M. Advances in epithelial ovarian cancer. Aust J Gen Pract. 2020;49(10):665-9. https://doi.org/10.31128/AJGP-09-19-5098 PMid:33015682 DOI: https://doi.org/10.31128/AJGP-09-19-5098
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet (London, England). 2015;386(9990):249-57. https://doi.org/10.1016/S0140-6736(14)62223-6 PMid:26002111 DOI: https://doi.org/10.1016/S0140-6736(14)62223-6
Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Hoppenau B, et al. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie ovarian cancer study group (AGO-OVAR). Gynecol Oncol. 2006;100(2):300-7. https://doi.org/10.1016/j.ygyno.2005.08.029 PMid:16199079 DOI: https://doi.org/10.1016/j.ygyno.2005.08.029
Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K. Advanced ovarian cancer: Primary or interval debulking? Five categories of patients in view of the results of randomized trials and tumor biology: Primary debulking surgery and interval debulking surgery for advanced ovarian cancer. Oncologist. 2016;21(6):745-54. https://doi.org/10.1634/theoncologist.2015-0239 PMid:27009938 DOI: https://doi.org/10.1634/theoncologist.2015-0239
Fourcadier E, Trétarre B, Gras-Aygon C, Ecarnot F, Daurès JP, Bessaoud F. Under-treatment of elderly patients with ovarian cancer: A population based study. BMC Cancer. 2015;15:937. DOI: https://doi.org/10.1186/s12885-015-1947-9
Corvino R, De Iuliis F, D’Aniello D, Cefalì K, Ferraro E, Lamazza A, et al. Long-lasting stent placement in an elderly advanced ovarian cancer patient. Oncol Res Treat. 2016;39(3):146-8. https://doi.org/10.1159/000444273 PMid:27031123 DOI: https://doi.org/10.1159/000444273
Balducci L, Cohen HJ, Engstrom PF, Ettinger DS, Halter J, Gordon LI, et al. Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005;3(4):572-90. https://doi.org/10.6004/jnccn.2005.0032 PMid:16038647 DOI: https://doi.org/10.6004/jnccn.2005.0032
Pectasides D, Papaxoinis G, Fountzilas G, Aravantinos G, Bamias A, Pavlidis N, et al. Epithelial ovarian cancer in Greece: A retrospective study of 1,791 patients by the Hellenic cooperative oncology group (HeCOG). Anticancer Res. 2009;29(2):745-51. PMid:19331231
Kotsopoulos J, Moody JR, Fan I, Rosen B, Risch HA, McLaughlin JR, et al. Height, weight, BMI and ovarian cancer survival. Gynecol Oncol. 2012;127(1):83-7. https://doi.org/10.1016/j.ygyno.2012.05.038 PMid:22713293 DOI: https://doi.org/10.1016/j.ygyno.2012.05.038
Makar AP, Baekelandt M, Tropé CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995;56(2):175-80. https://doi.org/10.1006/gyno.1995.1027 PMid:7896181 DOI: https://doi.org/10.1006/gyno.1995.1027
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Prim. 2016;2:16061. PMid:27558151 DOI: https://doi.org/10.1038/nrdp.2016.61
Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, et al. Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer. 2011;21(8):1422-7. https://doi.org/10.1097/IGC.0b013e31822c7704 PMid:21997170 DOI: https://doi.org/10.1097/IGC.0b013e31822c7704
Bilici A, Salepci T, Dane F, Gumus M, Ustaalioglu BBO, Seker M, et al. Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: A single centre experience. Arch Gynecol Obstet. 2010;282(4):417-25. https://doi.org/10.1007/s00404-009-1330-7 PMid:20035339 DOI: https://doi.org/10.1007/s00404-009-1330-7
van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological cancer cooperative group of the European organization for research and treatment of cancer. N Engl J Med. 1995;332(10):629-34. https://doi.org/10.1056/NEJM199503093321002 PMid:7845426 DOI: https://doi.org/10.1056/NEJM199503093321002
Morice P, Brehier-Ollive D, Rey A, Atallah D, Lhommé C, Pautier P, et al. Results of interval debulking surgery in advanced stage ovarian cancer: An exposed-non-exposed study. Ann Oncol. 2003;14(1):74-7. https://doi.org/10.1093/annonc/mdg003 PMid:12488296 DOI: https://doi.org/10.1093/annonc/mdg003
Leary A, Cowan R, Chi D, Kehoe S, Nankivell M. Primary surgery or neoadjuvant chemotherapy in advanced ovarian cancer: The debate continues. Am Soc Clin Oncol Educ B. 2016;35:153-62. https://doi.org/10.1200/EDBK_160624 PMid:27249696 DOI: https://doi.org/10.1200/EDBK_160624
Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM, Horowitz NS, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol. 2012;19(3):959-65. https://doi.org/10.1245/s10434-011-2100-x PMid:21994038 DOI: https://doi.org/10.1245/s10434-011-2100-x
Traina TA, Dugan U, Higgins B, Kolinsky K, Theodoulou M, Hudis CA, et al. Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. Breast Dis. 2010;31(1):7-18. https://doi.org/10.3233/BD-2009-0290 PMid:20519801 DOI: https://doi.org/10.3233/BD-2009-0290
Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzin. Cancer. 2009;115(6):1234-44. https://doi.org/10.1002/cncr.24149 PMid:19189349 DOI: https://doi.org/10.1002/cncr.24149
Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26-31. https://doi.org/10.1016/j.ygyno.2009.03.018 PMid:19395008 DOI: https://doi.org/10.1016/j.ygyno.2009.03.018
Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol. 1998;69(2):103-8. https://doi.org/10.1006/gyno.1998.4955 PMid:9600815 DOI: https://doi.org/10.1006/gyno.1998.4955
Scarabelli C, Gallo A, Franceschi S, Campagnutta E, De G, Giorda G, et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer. 2000;88(2):389-97. https://doi.org/10.1002/(sici)1097-0142(20000115)88:2<389:aid-cncr21>3.0.co;2-w PMid:10640973 DOI: https://doi.org/10.1002/(SICI)1097-0142(20000115)88:2<389::AID-CNCR21>3.0.CO;2-W
Tropé CG, Elstrand MB, Sandstad B, Davidson B, Oksefjell H. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV? Eur J Cancer. 2012;48(14):2146-54. https://doi.org/10.1016/j.ejca.2012.01.031 PMid:22382201 DOI: https://doi.org/10.1016/j.ejca.2012.01.031
Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: An exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol. 2010;17(6):1642-8. https://doi.org/10.1245/s10434-010-0964-9 PMid:20165986 DOI: https://doi.org/10.1245/s10434-010-0964-9
Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72(3):27887. https://doi.org/10.1006/gyno.1998.5145 PMid:10053096 DOI: https://doi.org/10.1006/gyno.1998.5145
Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Tropé CG. Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective. Acta Obstet Gynecol Scand. 2012;91(3):308-17. DOI: https://doi.org/10.1111/j.1600-0412.2011.01316.x
Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, et al. Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study. Gynecol Oncol. 2001;81(3):398-403. https://doi.org/10.1006/ gyno.2001.6172 PMid:11371128 DOI: https://doi.org/10.1006/gyno.2001.6172
Munkarah AR, Hallum AV 3rd, Morris M, Burke TW, Levenback C, Atkinson EN, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol. 1997;64(1):13-7. PMid:8995541 DOI: https://doi.org/10.1006/gyno.1996.4540
Colombo N, Sessa C, Du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019;29(4):728-60. https://doi.org/10.1093/annonc/mdz062 PMid:31046081 DOI: https://doi.org/10.1136/ijgc-2019-000308
Fu Y, Wang X, Pan Z, Xie X. Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: A retrospective study of 251 cases. Front Med China. 2014;8(1):91-5. https://doi.org/10.1007/s11684-014-0305-7 PMid:24370920 DOI: https://doi.org/10.1007/s11684-014-0305-7
Hosono S, Kajiyama H, Mizuno K, Sakakibara K, Matsuzawa K, Takeda A, et al. Comparison between serous and nonserous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery. Int J Clin Oncol. 2011;16(5):524-32. https://doi.org/10.1007/s10147-011-0223-5 PMid:21431342 DOI: https://doi.org/10.1007/s10147-011-0223-5
Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A gynecologic oncology group study. J Clin Oncol. 2008;26(1):83-9. https://doi.org/10.1200/JCO.2007.13.1953 PMid:18025437 DOI: https://doi.org/10.1200/JCO.2007.13.1953
Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol. 2001;82(3):532-7. https://doi.org/10.1006/gyno.2001.6328 PMid:11520151 DOI: https://doi.org/10.1006/gyno.2001.6328
Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: A gynecologic oncology group study. J Clin Oncol. 2007;25(24):3621-7. https://doi.org/10.1200/JCO.2006.10.2517 PMid:17704411 DOI: https://doi.org/10.1200/JCO.2006.10.2517
Bun S, Yunokawa M, Ebata T, Shimomura A, Shimoi T, Kodaira M, et al. Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2016;78(4):745-52. https://doi.org/10.1007/s00280-016-3100-0 PMid:27522647 DOI: https://doi.org/10.1007/s00280-016-3100-0
Ørskov M, Iachina M, Guldberg R, Mogensen O, Nørgård BM. Predictors of mortality within 1 year after primary ovarian cancer surgery: A nationwide cohort study. BMJ Open. 2016;6(4):e010123. https://doi.org/10.1136/bmjopen-2015-010123 PMid:27103625
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Hariyono Winarto, Adithya Welladatika, Muhammad Habiburrahman, Gatot Purwoto, Fitriyadi Kusuma, Tofan Widya Utami, Andi Darma Putra, Tricia Anggraeni, Kartiwa Hadi Nuryanto (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
